Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.
dc.contributor.author | Pietschmann, Thomas | |
dc.date.accessioned | 2017-04-21T10:35:55Z | |
dc.date.available | 2017-04-21T10:35:55Z | |
dc.date.issued | 2017-01-15 | |
dc.identifier.citation | Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. 2017, 91 (2) J. Virol. | en |
dc.identifier.issn | 1098-5514 | |
dc.identifier.pmid | 27807238 | |
dc.identifier.doi | 10.1128/JVI.01914-16 | |
dc.identifier.uri | http://hdl.handle.net/10033/620901 | |
dc.description.abstract | Chronic hepatitis C virus (HCV) infection causes severe liver disease and affects ca. 146 million individuals. Novel directly acting antivirals targeting HCV have revolutionized treatment. However, high costs limit access to therapy. Recently, several related drugs used in humans to treat allergies or as neuroleptics emerged as potent HCV cell entry inhibitors. Insights into their antiviral modes of action may increase opportunities for drug repurposing in hepatitis C and possibly other important human viral infections. | |
dc.language.iso | en | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.title | Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. | en |
dc.type | Article | en |
dc.contributor.department | TwinCore, Zentrum für experimentelle und klinische Infektionsforschung GmbH, Feodor-Lynen Str. 7, 30625 Hannover, Germany. | en |
dc.identifier.journal | Journal of virology | en |
refterms.dateFOA | 2017-05-02T00:00:00Z | |
html.description.abstract | Chronic hepatitis C virus (HCV) infection causes severe liver disease and affects ca. 146 million individuals. Novel directly acting antivirals targeting HCV have revolutionized treatment. However, high costs limit access to therapy. Recently, several related drugs used in humans to treat allergies or as neuroleptics emerged as potent HCV cell entry inhibitors. Insights into their antiviral modes of action may increase opportunities for drug repurposing in hepatitis C and possibly other important human viral infections. |